A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

Trial Profile

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Docetaxel (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018.
    • 13 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Apr 2016 Planned number of patients changed from 750 to 788 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top